The biggest risk is not whether Vicor’s technology works, but whether it scales fast enough and broadly enough to justify a
premium valuation. A delayed second-capacity path, slower
Gen5 production proof, concentrated customer exposure, or less-repeatable royalty economics could all lead to solid business progress but weaker shareholder returns than bulls expect.